Streetbeat News

Analyst Ratings

DD

DuPont de Nemours's (NYSE:DD) short percent of float has risen 3.45% since its last report, with 9.61 million shares sold short, which is 2.1% of all regular shares available for trading. It would take traders 3.42 days to cover their short positions on average. The company's short interest is less than its peer group average of 3.64%.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 4:00 pm

TWLO

Goldman Sachs analyst Kash Rangan has maintained a Neutral rating on Twilio (NYSE:TWLO) and raised the price target from $53 to $67.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 3:59 pm

LYFT

Lyft Inc's Q2 earnings beat expectations, leading to a rise in Q3 guidance. However, analysts are concerned about Q4 due to the company's insurance renewal which is expected to heavily impact margins. Despite this, Lyft's pricing and driver supply are improving, and ride growth has rebounded. Analysts from RBC Capital Markets, Susquehanna, and Needham have maintained neutral ratings on the stock, with price targets ranging from $9 to $12.

Portfolio Pulse from Priya Nigam

August 09, 2023 | 3:59 pm

TDUP

Goldman Sachs analyst Alexandra Steiger maintains a Neutral rating on ThredUp (NASDAQ:TDUP) and raises the price target from $3 to $4.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 3:58 pm

TTGT

Goldman Sachs analyst Kash Rangan has maintained a 'Sell' rating on TechTarget (NASDAQ:TTGT) but raised the price target from $27 to $30.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 3:57 pm

LPSN

Craig-Hallum analyst Jeff Van Rhee has upgraded LivePerson (NASDAQ:LPSN) from Hold to Buy and raised the price target from $5 to $7.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 3:57 pm

SQSP

Goldman Sachs analyst Gabriela Borges maintains a Neutral rating on Squarespace (NYSE:SQSP) and raises the price target from $30 to $34.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 3:56 pm

RBC

Alembic Global has upgraded RBC Bearings from Neutral to Overweight and set a new price target of $267. The upgrade was announced by analyst Peter Skibitski.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 3:56 pm

SAGE

Goldman Sachs analyst Salveen Richter maintains a Neutral rating on Sage Therapeutics and lowers the price target from $75 to $22.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 3:55 pm

TJX

Cleveland Research has upgraded TJX Companies from Neutral to Buy.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 3:55 pm